Feasibility and safety of uniportal thoracoscopy for chronic pulmonary aspergillosis

Sci Rep. 2023 Sep 30;13(1):16480. doi: 10.1038/s41598-023-43781-9.

Abstract

Surgery plays a crucial role in the treatment of patients with chronic pulmonary aspergillosis (CPA). However, there is currently limited information available regarding the use of uniportal thoracoscopy (Uni-VATS) in CPA patients. To address this gap, we conducted a retrospective analysis of surgical procedures performed at a single center, aiming to demonstrate the feasibility and safety of Uni-VATS for patients with CPA. We collected basic information and surgical data from patients who underwent surgery for CPA at our hospital between January 2018 and June 2022. All patients received voriconazole antifungal medication for 3-6 months post-surgery and were monitored for a minimum of 6 months. A total of 110 patients, comprising 59 cases in the traditional open chest incision group and 51 cases in the Uni-VATS group, met the inclusion criteria. Among those who underwent surgery, 70% were male (77/110). The median age (IQR) of all enrolled patients was 55 (46-62) years. There were no statistically significant differences in general information, such as age, sex, comorbidities, BMI, FEV1, FVC, clinical symptoms, location of the disease, and duration of voriconazole antifungal medication, between the OS group and the Uni-VATS group (p > 0.05). The postoperative complication rates were 40.7% (24/59) for the traditional open chest incision group and 17.6% (9/51) for the Uni-VATS group. Through univariate analysis, we identified sex and operative approach as risk factors for postoperative complications. Multivariate logistic analysis confirmed that male and OS procedures were the independent risk factors for postoperative complications. There were statistically significant differences in operative time, intraoperative blood loss volume, postoperative drainage volume, pain scores, postoperative drainage tube removal time, postoperative hospital stay time between the OS group and the Uni-VATS group (p < 0.05). Uni-VATS is a feasible and safe surgical procedure for patients with CPA, and we recommend it as a preferred option for selected patients with CPA.

MeSH terms

  • Antifungal Agents / therapeutic use
  • Feasibility Studies
  • Female
  • Humans
  • Lung Neoplasms* / surgery
  • Male
  • Middle Aged
  • Postoperative Complications / etiology
  • Pulmonary Aspergillosis* / drug therapy
  • Pulmonary Aspergillosis* / etiology
  • Pulmonary Aspergillosis* / surgery
  • Retrospective Studies
  • Thoracic Surgery, Video-Assisted / methods
  • Voriconazole / therapeutic use

Substances

  • Antifungal Agents
  • Voriconazole